Drug Trial Radar · NCT04797104
Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
478
Actual
Start
Apr 22, 2021
Primary completion
Jul 30, 2023
Study completion Dec 5, 2023
Sponsor
- Lead sponsor
- LIB Therapeutics LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Mar 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to assess LDL-C reductions at Week 24 and the mean of Weeks 22 and 24 with monthly Q4W (≤31 days) dosing of LIB003 300 mg administered subcutaneously (SC) compared to placebo in patients 18 years or older with Heterozygous FH on stable diet and oral LDL-C lowering drug therapy.
Conditions
- Heterozygous Familial Hypercholesterolemia
Interventions
lerodalcibepDrug
300 mg Q4W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula at Week 24Time frame: Baseline and Week 24
- Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula Using the Mean of Weeks 22 and 24Time frame: Baseline and Week 24
Locations
7 sites in 5 countries. Site status is shown where the registry gives one.
Metabolic & Atherosclerosis Research Center (MARC)
Cincinnati, Ohio
Rabin Medical Center, Beilinson Hospital,
Petah Tikva, Israel
Department of Medicine, Hadassah University Hospital
Jerusalem, Jerusalem, Israel
Lipid Clinic, Oslo University Hospital
Oslo, Norway
Carbohydrate and Lipid Metabolism Research Unit
Johannesburg, Gauteng, South Africa
Division of Lipidology, Department of Medicine University of Cape Town
Cape Town, Western Province, South Africa
Ege University Medical School
Izmir, Bornova, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.